The Pharmacology of Acute Lung Injury in Sepsis
Acute lung injury (ALI) secondary to sepsis is one of the leading causes of death in sepsis. As such, many pharmacologic and nonpharmacologic strategies have been employed to attenuate its course. Very few of these strategies have proven beneficial. In this paper, we discuss the epidemiology and pat...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Advances in Pharmacological Sciences |
| Online Access: | http://dx.doi.org/10.1155/2011/254619 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562888570568704 |
|---|---|
| author | Brian Michael Varisco |
| author_facet | Brian Michael Varisco |
| author_sort | Brian Michael Varisco |
| collection | DOAJ |
| description | Acute lung injury (ALI) secondary to sepsis is one of the leading causes of death in sepsis. As such, many pharmacologic and nonpharmacologic strategies have been employed to attenuate its course. Very few of these strategies have proven beneficial. In this paper, we discuss the epidemiology and pathophysiology of ALI, commonly employed pharmacologic and nonpharmacologic treatments, and innovative therapeutic modalities that will likely be the focus of future trials. |
| format | Article |
| id | doaj-art-894442a41ad04d4b82962aa6e3139484 |
| institution | Kabale University |
| issn | 1687-6334 1687-6342 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Pharmacological Sciences |
| spelling | doaj-art-894442a41ad04d4b82962aa6e31394842025-02-03T01:21:35ZengWileyAdvances in Pharmacological Sciences1687-63341687-63422011-01-01201110.1155/2011/254619254619The Pharmacology of Acute Lung Injury in SepsisBrian Michael Varisco0Division of Critical Care, Cincinnati Children's Hospital Medical Center, MLC 2005, Cincinnati, OH 45229-3039, USAAcute lung injury (ALI) secondary to sepsis is one of the leading causes of death in sepsis. As such, many pharmacologic and nonpharmacologic strategies have been employed to attenuate its course. Very few of these strategies have proven beneficial. In this paper, we discuss the epidemiology and pathophysiology of ALI, commonly employed pharmacologic and nonpharmacologic treatments, and innovative therapeutic modalities that will likely be the focus of future trials.http://dx.doi.org/10.1155/2011/254619 |
| spellingShingle | Brian Michael Varisco The Pharmacology of Acute Lung Injury in Sepsis Advances in Pharmacological Sciences |
| title | The Pharmacology of Acute Lung Injury in Sepsis |
| title_full | The Pharmacology of Acute Lung Injury in Sepsis |
| title_fullStr | The Pharmacology of Acute Lung Injury in Sepsis |
| title_full_unstemmed | The Pharmacology of Acute Lung Injury in Sepsis |
| title_short | The Pharmacology of Acute Lung Injury in Sepsis |
| title_sort | pharmacology of acute lung injury in sepsis |
| url | http://dx.doi.org/10.1155/2011/254619 |
| work_keys_str_mv | AT brianmichaelvarisco thepharmacologyofacutelunginjuryinsepsis AT brianmichaelvarisco pharmacologyofacutelunginjuryinsepsis |